The deal size was increased to $200M from $150M and priced at low end of $9.00-$9.50 range. JPMorgan, Leerink and Guggenheim are acting as joint book running managers for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COGT:
- Cogent Biosciences $150M Spot Secondary; price range $9.00-$9.50
- Cogent Biosciences offers to sell $150M in common stock
- Cogent Biosciences price target raised to $22 from $12 at H.C. Wainwright
- Cogent Biosciences price target raised to $9 from $7 at Baird
- Promising Outlook for Cogent Biosciences: Bezuclastinib’s Potential in Systemic Mastocytosis and Beyond